AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
The regulatory body has approved Tagrisso for the treatment of unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) in adult patients whose disease has not progressed following treatment with chemoradiotherapy. Following the latest nod, Tagrisso is now indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations, as determined by an FDA-approved test. Year to date, shares of AstraZeneca have gained 15.1% compared with the industry's rise of 22.8%. Image Source: Zacks Investment Research Tagrisso Latest Approval Based on AZN's LAURA Study The latest label expansion nod for Tagrisso was based on data from the phase III LAURA study. Data from the study showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% versus placebo. Also, patients treated with Tagrisso experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients who were treated with a placebo
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- US' first self-administered flu vaccine could increase accessibility and uptake [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Tagrisso gains FDA approval for stage III NSCLC [Yahoo! Finance]Yahoo! Finance
- AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy? [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication [Yahoo! Finance]Yahoo! Finance
- Qure.ai secures $65m in Series B financing to expand into US and other markets [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 9/26/24 - Form 6-K
- 9/23/24 - Form 6-K
- 9/23/24 - Form 6-K
- AZN's page on the SEC website